Coherus BioSciences. Jefferies 2016 Healthcare Conference. June 8, Copyright 2016 All Rights Reserved.
|
|
- Carmella Parrish
- 5 years ago
- Views:
Transcription
1 Coherus BioSciences Jefferies 2016 Healthcare Conference June 8, 2016 Copyright 2016 All Rights Reserved.
2 Forward Looking Statements Except for the historical information contained herein, the matters set forth in this presentation, including statements regarding Coherus plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies, product pipeline, clinical studies, product development, release of data and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including Coherus expectations regarding its ability to advance its CHS-1701, CHS- 0214,CHS-1420, CHS-5217 and CHS-3351 biosimilar drug candidates, complete bridging studies for CHS-0214 and CHS- 1420, complete its follow-on PK/PD study for CHS-1701, file BLAs for CHS-1701 and CHS-1420 in the U.S., file an MAA for CHS-0214 in the E.U., file at least one IND on a second wave biosimilar pipeline candidate and enter into collaborations for CHS-1701 commercialization ex-u.s. and for its immunology (Anti-TNF) pipeline. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our biosimilar drug candidates. Coherus undertakes no obligation to update or revise any forwardlooking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus business in general, see Coherus Quarterly Report on Form 10-Q for the period ended March 31, 2016 and its future periodic reports to be filed with the Securities and Exchange Commission. 2 Copyright 2016 All Rights Reserved.
3 Agenda Introduction and Company Summary Program Highlights The Commercial Opportunity 3 Copyright 2016 All Rights Reserved.
4 Coherus BioSciences is a Leading Pure Play Biosimilars Company Team Platform Leadership team includes pioneers of top-selling biologics Market Opportunity >$100 billion in biologics revenues facing patent expiration by 2020 Decreasing commercial, regulatory and IP uncertainties Pipeline Strategy Commercialize US oncology Out-license global anti-tnfs Expect 1 to 2 new INDs per year 4 Copyright 2016 All Rights Reserved.
5 Megatrends Drive >$100 Billion Opportunity Surge in patent expirations Healthcare reform / regulatory enablement Better analytic tools enable comparability >$100 Billion In 2015 Originator Global Sales Payer need for biologics cost control Source: EvaluatePharma: 29 originator products with > $1 B in global sales losing patent exclusivity in at least one major market through 2020 had ~$106 B in 2015 global sales 5 Copyright 2016 All Rights Reserved.
6 Key Uncertainties Continue to Decline and Path to Market has Become More Clear Uncertainty (1) Higher Lower Affordable Care Act Zarxio is a registered trademark of Novartis AG (1) Trend lines illustrative in nature (2) Anticipated 6 Copyright 2016 All Rights Reserved. Zarxio approval Zarxio launch Evolving payor / provider sentiment Patent dance rulings CHRS 135 IPR institution IPR wins for biosimilars (2) Celltrion approval Additional launches (2) We are persuaded that there is a reasonable likelihood that [Coherus] would prevail in showing claims 1 5 of the 135 patent are unpatentable USPTO Institution decision IPR vs. AbbVie patent 135 Commercial Patent Approval Pathway Time
7 2016 is a Transformational Year with Multiple Program Milestones and Catalysts CHS-1701 pegfilgrastim biosimilar 1Q 2Q Immuno data positive (2) PD data positive (3) Follow-up PK/PD read-out (1) BLA (1) 3Q 4Q 1Q 2Q Anticipated approval 3Q 4Q CHS-1420 adalimumab biosimilar Ph 3 top-line data Completed Ph 3 enrollment 135 IPR institution 166 IPR decision Ph 3 study read-out BLA 135 patent invalidity decision Anticipated approval 166 patent invalidity decision CHS-0214 etanercept biosimilar Ph 3 RA data positive (2) Ph 3 Psoriasis data positive (3) MAA Anticipated approval Wave 2 Announced Lucentis and Avastin biosimilar programs Unless otherwise noted, catalysts placed within 3 month achievement windows (1) Expect to complete study late in the first half of this year & move forward with BLA filing directly thereafter; (2) Announced in 1Q 16; (3) Announced in 4Q 15 7 Copyright 2016 All Rights Reserved.
8 US Regulatory Pathway is Established and Full-label Extrapolation is Achievable Concentration (µg/ml) Time (hr) Phase 3 Clinical Trials Pivotal Phase 1 Human PK/PD Study In vivo Animal Comparability Analytical Characterization and in vitro Comparability Cell Line Development and Manufacturing Concentration (µg/ml) Enbrel (EU) CHS-0214 DP Enbrel (EU) Time (hr) Critical quality attributes determine biological activity Deep understanding of the originator attributes is critical for regulatory success Totality of the data drives fullindication labeling Zarxio and Celltrion both approved with full label under 351(k) pathway 8 Copyright 2016 All Rights Reserved.
9 Differentiated Platform Navigates the Pathway to Approval Cutting Edge Analytics Process Science and Molecular Tuning Clinical and Regulatory Intellectual Property Highly engaged SAB Develop own IP 9 Copyright 2016 All Rights Reserved.
10 Agenda Introduction and Company Summary Program Highlights The Commercial Opportunity 10 Copyright 2016 All Rights Reserved.
11 CHS-1701 Pegfilgrastim Biosimilar Provides Near-term Commercial Opportunity Clinical and Regulatory Complex, well defined molecule with limited heterogeneity Achieved high-level of analytical similarity Successful scale-up, stable formulation Secured commercial supply through long-term agreement with KBI Efficacy demonstrated in healthy volunteers Successful immunogenicity trial >300 subjects Large Revenue Opportunity Neulasta WW annual revenues $ billion Favorable Competitive Profile Status late-stage biosimilar pipeline 1 Expect to file after BLA-enabling study completion in 2Q 16 Key patents either expired or avoided (1) With U.S. FDA registration focus Source: EvaluatePharma, First Word 11 Copyright 2016 All Rights Reserved. File accepted in Oct 15 no adcom. scheduled to date File accepted in Nov 14 BSUFA date passed in mid 2015
12 High-quality Commercial Manufacturing for CHS-1701 in Place to Exploit the Global Opportunity Key Partnership Terms with KBI Term COGS Current capacity commitment 3 years with options to extend ~5% of sales price ~$1B in annual sales Cornerstone of US oncology franchise Unencumbered global rights to ~$5B market opportunity Loading supply chain to support mid 2017 launch Readiness status Qualification lots completed Inspection ready Low COGS secures long-term sustainability 12 Copyright 2016 All Rights Reserved.
13 CHS-0214 Etanercept Biosimilar Addresses Large Commercial Opportunity A very complex biological on the market High similarity match with originator Large Revenue Opportunity Enbrel WW annual revenues $ billion Clinical and Regulatory Successful pre-commercial scale-up Stable proprietary formulation Positive top-line Ph 3 results in RA Positive top-line Ph 3 results in psoriasis Key EU patents either expired or avoided Issued patent on non-infringing formulation Coherus holds US rights Modest Competition Status late-stage biosimilar pipeline 1 Expect to file after Ph 3 data readout in 2H 16 Filed both in EU and US in 2015 Approved in EU in 2016 (1) With U.S. FDA registration focus Source: EvaluatePharma, First Word 13 Copyright 2016 All Rights Reserved.
14 CHS-1420 Adalimumab Biosimilar Strong Analytical Match and IP Leadership Position. Top-line Ph 3 Data Mid Year High-level of analytical similarity achieved Large Revenue Opportunity Humira WW annual revenues $ billion Clinical and Regulatory Scale-up according to plan CMOs in pre-agreement for commercial supply Enrollment for Ph 3 in psoriasis completed Ph 3 read-out and subsequent filing expected in H2 16 CHRS wins IPR institution vs. AbbVie 135 Coherus awarded 3 formulation patents CHRS files IPR against AbbVie 166 (1) With U.S. FDA registration focus Source: EvaluatePharma, First Word 14 Copyright 2016 All Rights Reserved IP Hurdles Expected to Limit Competition Status late-stage biosimilar pipeline 1 Several others Expect to file after Ph 3 study completion in 2H 16 Filed in Nov 15 formulation IPRs not instituted In different development stages unclear IP strategy
15 Successful Implementation of Differentiated IP Strategy for CHS-1420 Adalimumab Biosimilar 1 Successfully instituted an IPR against AbbVie s dosing patent Worked around AbbVie formulation patents 157 and 158 and developed own IP the combination of these could represent significant hurdles for other market players 3 The rest of the IP strategy, including the 166 IPR, aims for a clear path to market 15 Copyright 2016 All Rights Reserved.
16 1 Management Experience and Legal Savvy Enabled Institution of 135 IPR Proven experience Cohesive IP strategy Validated by IPR institution Clear path to market Industry leading management team has three decades of biologics experience Understanding the difference between valid and contrived IP Awarded three patents PTAB accepted Coherus arguments for institution Plan to launch on approval IPR Institution Selected Excerpts [AbbVie s] arguments are premised on a claim construction that we do not adopt a skilled artisan would have been led to optimize the dosing regimens disclosed in [Van de Putte and Kempeni] we are unpersuaded by [AbbVie s] arguments regarding superiority of the 40 and 80 mg doses to the 20 mg dose 16 Copyright 2016 All Rights Reserved.
17 2 Coherus Patents for Adalimumab Formulations Excluding Polyol / Surfactant Represent Hurdle for Other Players Combined impact of Coherus and AbbVie patents related to use of surfactant and/or polyol in adalimumab formulation Use surfactant? Use polyol? Use Both? No 880 Yes 157 No Yes 158 Use Neither Yes 157 and 158 Other biosimilar players must address either AbbVie or Coherus patents to enter market before 2H 2022 CHRS potential to be only player in market if others fail to address these patents Amgen 157 and 158 IPRs were not instituted U.S. patents 8,916,157, 8,916,158, 9,346,880, 9,340,611, and 9,340,612; 17 Copyright 2016 All Rights Reserved.
18 3 Expect IPRs to Succeed, Derisk Launch, and Aim for a Clear Path to Market Timeline of Coherus IPRs filed on AbbVie Humira dosing and formulation patents 135 IPR 166 IPR 2015 Nov U.S. patents 9,114,166 and 8,889,135 (1) Must occur within six months of filing (2) Must occur within 12 months of institution 1420 approval (3) USPTO - Protecting Biopharmaceutical Innovation Litigation and Patent Office Procedures - Janet Gongola, Senior Advisor (4) Law360 March 8, Copyright 2016 All Rights Reserved May Nov 2017 May Filed Instituted Final decision (2) Filed Institution decision (1) Nov Final decision (2) Anticipated CHS- Approx. 70% of instituted IPRs result in claim invalidation or settlement (3) Appeals to Federal Circuit of PTO final IPR decisions have failed at a rate of ~90% (4)
19 There are Significant Misbeliefs Relating to Humira IP No Humira biosimilar would launch at risk IPR appeals will delay biosimilar launches Preliminary injunctions will block most biosimilar launches Risk of treble damages will dissuade launches Absent preliminary injunction, Coherus expects to launch its Humira biosimilar upon approval IPR final decisions have ~90% probability of being affirmed on appeal (1) reducing likelihood of preliminary injunction Burden for preliminary injunction is high and statistics show success is low AbbVie patents subject to strong invalidity arguments are expected to be ineligible for treble damages (1) Law360 March 8, Copyright 2016 All Rights Reserved.
20 Agenda Introduction and Company Summary Program Highlights The Commercial Opportunity 20 Copyright 2016 All Rights Reserved.
21 Coherus Applies Rigorous Selection Criteria to Candidate Molecules Major biologics losing patent exclusivity by 2020 Generic name WW sales in 2015 (US$ billion) adalimumab 14.4 etanercept 9.1 infliximab 8.1 rituximab 7.3 insulin glargine 7.1 bevacizumab 6.9 trastuzumab 6.8 pegfilgrastim 4.8 ranibizumab 3.6 insulin aspart rec 3.1 insulin lispro rec 2.8 onabotulinumtoxina 2.8 insulin detemir rec 2.7 interferon beta-1a 2.6 factor VIII (procoag.) 2.2 omalizumab 2.1 interferon beta-1a 2.0 Coherus natalizumab 1.9 wave 1 assets epoetin alfa 1.9 insulin aspart 1.7 Coherus cetuximab 1.5 wave 2 assets Toclizumab 1.5 Assessment Development to Phase 1 Phase 3 Commercial Market Opportunity Patents & IP Analysis Technical Analysis Molecule and Analytics Cell line and Manufacturing Clinical and Nonclinical Harmonization Global Sites Co-therapies Payers, Providers, Patients Partners Promotion Legal Defense All technical and commercial factors must be holistically evaluated at key decision points Patent expiry and large existing markets are insufficient rationale for product selection Source: EvaluatePharma 21 Copyright 2016 All Rights Reserved.
22 Therapeutic Area Franchises Link Coherus Capabilities with Customer Needs Create therapeutic verticals Platform Capability Strategy Market Conversion Opportunity Platform enables development of biosimilar candidates Product pipeline to leverage commercialization infrastructure 22 Copyright 2016 All Rights Reserved.
23 Market Differences Drive Tailored Commercial Responses Oncology (CHS-1701) Inflammation (Anti-TNFs) Market Dynamics Episodic, non-chronic care Multi-indication, chronic care Concentrated sites, clinic and hospital Larger, multiple specialist prescriber base GPO and provider driven adoption Payer driven adoption, PBM intermediary Lower competitive intensity Higher competitive intensity Commercial Response Specialty sales force < 50 Specialty sales force > 150, Payer contracting GPO and provider contracting Competitive patient friendly formats / programs Education and conversion dynamics executable Strong sales pull-through driving rapid conversion 23 Copyright 2016 All Rights Reserved.
24 Potential Platform Throughput Enables Therapeutic Franchise Focus to Maximize Market Value Therapeutic Area Franchises Oncology Immunology (Anti-TNF) Ophthalmology (VEGF) Multiple Sclerosis Products CHS-1701 / BE (1) CHS-5217 / PC CHS-AAA / PC CHS-1420 / Ph 3 CHS-0214 / Ph 3 CHS-BBB / PC CHS-3351 / PC CHS-CCC / PC CHS-131 / Ph 2b CHS-DDD / PC Commercial Model Options (1) BLA enabling Wave 1 Wave 2 Potential Favorable industry structure yields reasonably sized commercial footprint Favorable Strategic Deal or Retain Open Open Pending Data 24 Copyright 2016 All Rights Reserved.
25 Program Development Timing and Milestones CHS-1701 (pegfilgrastim biosimilar) CHS-0214 (etanercept biosimilar) CHS-1420 (adalimumab biosimilar) Wave 2 assets Q2 15 PK/PD & immunogenicity studies initiated Q2 15 Phase 3 PsO & RA studies enrolled Q3 15 PsO study initiated H1 16 Bevacizumab & Ranibizumab announced Q1 16 Positive immunogenicity data Q4 15 Q1 16 Positive Ph 3 PsO data Positive Ph 3 RA data Mid IPR instituted Phase 3 readouts H2 16 Pipeline addition Q2 16 PK/PD readout (1) BLA filing directly thereafter (1) H2 16 MAA filing H2 16 BLA filing H1 17 Pipeline addition Unless otherwise noted, catalysts placed within 3 month achievement windows (1) Expect to complete study late in the first half of this year & move forward with BLA filing directly thereafter 25 Copyright 2016 All Rights Reserved.
26 Coherus BioSciences Jefferies 2016 Healthcare Conference June 8, 2016 Copyright 2016 All Rights Reserved.
Coherus BioSciences. Jefferies 2016 London Healthcare Conference. November 16, Copyright 2016 All Rights Reserved.
Coherus BioSciences Jefferies 2016 London Healthcare Conference November 16, 2016 Copyright 2016 All Rights Reserved. Forward Looking Statements Except for the historical information contained herein,
More informationCoherus BioSciences. 35 th Annual J.P. Morgan Healthcare Conference. January 10, Copyright 2016 All Rights Reserved.
Coherus BioSciences 35 th Annual J.P. Morgan Healthcare Conference January 10, 2017 Copyright 2016 All Rights Reserved. Forward Looking Statements Except for the historical information contained herein,
More informationCoherus BioSciences 2018 CANTOR GLOBAL HEALTHCARE CONFERENCE OCTOBER 2, Copyright 2018 All Rights Reserved.
Coherus BioSciences 2018 CANTOR GLOBAL HEALTHCARE CONFERENCE OCTOBER 2, 2018 Copyright 2018 All Rights Reserved. Forward Looking Statements This presentation does not constitute or form any part of any
More informationCORPORATE PRESENTATION January 2019
CORPORATE PRESENTATION January 2019 1 DISCLAIMER This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ( Outlook Therapeutics or the Company ) based on management s current
More informationWhat next? Manufacture the biosimilar product
What next? Manufacture the biosimilar product Design manufacturing process to match QTPP Full quality dossier required. Use state of the art technologies In accordance with relevant ICH and CHMP guidelines
More informationPharmaceutical Law & Industry Report
Pharmaceutical Law & Industry Report Reproduced with permission from Pharmaceutical Law & Industry Report, 16 PLIR 199, 02/09/2018. Copyright 2018 by The Bureau of National Affairs, Inc. (800-372-1033)
More informationCoherus BioSciences. 37th Annual J.P. Morgan Global Healthcare Conference January 8, Copyright 2019 All Rights Reserved.
Coherus BioSciences 37th Annual J.P. Morgan Global Healthcare Conference January 8, 2019 Copyright 2019 All Rights Reserved. Forward Looking Statements This presentation does not constitute or form any
More informationJefferies 2016 Healthcare Conference. June 7, 2016
Jefferies 2016 Healthcare Conference June 7, 2016 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management
More informationPfenex Inc. San Diego, CA NYSE MKT: PFNX. Updated July 2017
Pfenex Inc. San Diego, CA NYSE MKT: PFNX Updated July 2017 Safe Harbor Statement This presentation (the Presentation ) includes forward looking statements within the meaning of the Private Securities Litigation
More informationAn update on development strategies of recently approved biosimilars in Europe. Johanna Mielke
An update on development strategies of recently approved biosimilars in Europe Johanna Mielke Acknowledgement & disclaimer This project was supported by the Swiss State Secretariat for Education, Research
More informationPfenex Inc. San Diego, CA NYSE MKT: PFNX
Pfenex Inc. San Diego, CA NYSE MKT: PFNX Safe Harbor Statement This presentation (the Presentation ) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationGoldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during
More information29/04/2016. Biosimilars An NHS perspective. Aim. Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast April 2016
Biosimilars An NHS perspective Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast April 2016 Aim The changing medicines landscape driving patient access to medicines the Biosimilar
More informationIntellectual Property: Recent Developments and Implications
Intellectual Property: Recent Developments and Implications Nichole Gifford, Partner, Rothwell Figg Ernst & Manbeck P.C. World Biosimilar Congress May 24, 2017 Overview Introduction to Biologics Price
More informationEvolving U.S. Biosimilars Landscape
Evolving U.S. Biosimilars Landscape A Medical Affairs Perspective By Thao Sutter and Bryan Katz Syneos Health Consulting 2018 Syneos Health. All rights reserved. Introduction The U.S. biosimilar landscape
More informationTeva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference. Kåre Schultz President and CEO January 7, 2019
Teva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference Kåre Schultz President and CEO January 7, 2019 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm Overview of the Regulatory Pathway and FDA s Guidance for the Development and Approval of Biosimilar
More informationFirst Quarter 2018 Financial Results. May 8, 2018
First Quarter 2018 Financial Results May 8, 2018 Agenda Introduction Sarah Carmody, Senior Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer First Quarter
More informationInnovative Solutions for Global Health. Corporate Presentation
Innovative Solutions for Global Health Corporate Presentation Safe Harbor Statements This presentation ( Presentation ) contains forward-looking statements within the meaning of the Private Securities
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationJP Morgan Healthcare Conference January 9, 2012
JP Morgan Healthcare Conference January 9, 2012 SAFE HARBOR Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which are subject to a number
More informationRegulation of Biosimilars in Canada
Regulation of Biosimilars in Canada Session 2: Global Regulatory Trends of Biosimilars GBC 2018 June 28, 2018 Stephanie Hardy Office of Policy and International Collaboration Biologics and Genetic Therapies
More informationCorporate Presentation January 2019
Corporate Presentation January 2019 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management s current expectations
More informationBank of America Merrill Lynch Healthcare Conference. September 13, 2013
Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and
More informationNYSE American: PFNX Corporate Presentation
NYSE American: PFNX Corporate Presentation Pfenex Safe Harbor Statement This presentation, including the accompanying oral presentation (the Presentation ), includes forward-looking statements within the
More informationARIKAYCE U.S. FDA Approval
S E P T E M B E R 2 8, 2 0 1 8 ARIKAYCE U.S. FDA Approval Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the
More informationBiosimilar Development Clinical Investigator Considerations
Biosimilar Development Clinical Investigator Considerations June 2011 www.ppdi.com Biosimilar products are not new in the pharmaceutical industry. However, the pending expiration of numerous therapeutic
More informationPharmacovigilance in Oncology. Luis H. Camacho, MD, MPH Houston, USA
Pharmacovigilance in Oncology Luis H. Camacho, MD, MPH Houston, USA 5th European Biosimilar Congress - Valencia June 27-29, 2016 Disclosure Director, Center for Oncology and Blood Disorders. Secretary,
More informationLicense Agreement of Tildrakizumab for Psoriasis in Europe
License Agreement of Tildrakizumab for Psoriasis in Europe July 28 th 2016 Disclaimer This document has been prepared by Almirall, S.A. (the Company ) exclusively for use during the presentation. This
More informationMomenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. 36 th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation contains forward-looking statements about our financial outlook,
More informationBiosimilars 2016 Balancing Fast Uptake with Industry Sustainability. Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals
Biosimilars 2016 Balancing Fast Uptake with Industry Sustainability Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals 10 years on, biosimilars have had a strong impact on global healthcare
More informationBiosimilars Market Update
Biosimilars Market Update Panel: Matthew Brougham Consultant Economist, Brougham Consulting Inc Mark Jackson Consultant Pharmacist, TELUS Health Dr. Ed Keystone Professor of Medicine, University of Toronto
More informationMomenta Pharmaceuticals Reports First Quarter 2017 Financial Results
May 2, 2017 Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results --Company reports Glatopa 20 mg product revenues of $23 million, a 58% increase over the same period in 2016-- --Ended the
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationas they ordinarily would for a generic. This has been a key factor inhibiting biosimilar uptake.
PEB OVR 6.1 Agenda Item 6 BIOSIMILARS REIMBURSEMENT 1 Purpose of Item 1.1 The Minister (delegate) requests the Pharmaceutical Benefits Advisory Committee (PBAC) provide advice on the following matter(s)
More informationRaymond James 34th Annual Institutional Investors Conference
Raymond James 34th Annual Institutional Investors Conference Thomas Werner, CFO March 5, 2013 Safe Harbor This material contains forward-looking statements within the meaning of the U.S. federal securities
More informationBiomanufacturing Capacity for Biosimilars: Is there enough?
Biomanufacturing Capacity for Biosimilars: Is there enough? Cambridge Healthtech Institute s Third Annual BIOAnalytical Summit 2012 Mar 19-22 Baltimore, MD BioProcess Technology Consultants www.bptc.com
More informationpsivida Corp PSDV June 2016
psivida Corp PSDV June 2016 Safe Harbor Statement Safe Harbor Statement SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking,
More informationLEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS
LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based
More informationThe Future has Arrived: Biosimilars
The Future has Arrived: Biosimilars Overview of the Regulatory Framework and FDA s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US Sue Lim, M.D., Director
More informationREFERENCE CODE GDHC1113CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1113CFR PUBLICATION DATE M AY 2013 PSORIASIS - Executive Summary Sales for Psoriasis in China 2012 2022 We estimate the 2012 PsO drug sales to be $392.2m in China. By forecast end in
More informationFebruary September 11, See, for example, Guidance for Industry on Biosimilars: Q & As Regarding Implementation of the BPCI Act of 2009:
February 2014 Biosimilars: Strategic considerations for interchangeability The future timing, magnitude, and impact of the anticipated biosimilar wave continue to be in flux. Major biopharmaceutical manufacturers
More informationDance Dance Dance: Unveiling the Intricacy in Biosimilar Litigation
Dance Dance Dance: Unveiling the Intricacy in Biosimilar Litigation Peng Sun, Ph.D., J.D. Foley & Lardner LLP August 26, 2017 Attorney Advertising Prior results do not guarantee a similar outcome Models
More informationThe Future has Arrived: Biosimilars
The Future has Arrived: Biosimilars Overview of the Regulatory Framework and FDA s Guidance for the Development and Approval of Biosimilar and Interchangeable Products in the US Sue Lim, M.D., Director
More informationEXANE Conference. Jérôme Contamine, Executive Vice President, Chief Financial Officer. Paris June 13, 2017
EXANE Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Paris June 13, 2017 Forward Looking Statements This presentation contains forward-looking statements as defined in the
More informationFourth Quarter and Full Year 2017 Financial Results. February 21, 2018
Fourth Quarter and Full Year 2017 Financial Results February 21, 2018 Agenda Introduction Sarah Carmody, Director of Investor Relations Corporate Update Craig Wheeler, President and Chief Executive Officer
More informationForesee Pharmaceuticals, Inc.
Foresee Pharmaceuticals, Inc. Rapid Development and Commercialization of a Proprietary Sustained-release Depot Formulation of Leuprolide for the Treatment of Advanced Prostate Cancer PNWBIO Meeting 10
More informationREFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013 STELARA (PSORIASIS) - Executive Summary Table below presents key metrics for Stelara in the seven of the nine major pharmaceutical markets. Stelara:
More informationCorporate Overview. June 2017
Corporate Overview June 2017 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included
More informationRoche: adapting to the changing environment. Severin Schwan, CEO Roche Group London, 15 September 2010
Roche: adapting to the changing environment Severin Schwan, CEO Roche Group London, 15 September 2010 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationREFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - US Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in the US 2012 We estimate the 2012 PsO drug
More informationBiosimilars 101: How similar are they?
Biosimilars 101: How similar are they? Matthew Marston, Pharm.D., BCPS, BCOP Senior Manager of Clinical Pharmacy Services Miller Drug, LLC Outline Describe the approval and manufacturing process of biologics
More informationpsivida Transforms into Commercial Stage Specialty BioPharmaceutical Company ASCRS April 12, 2018 NASDAQ: EYPT
psivida Transforms into Commercial Stage Specialty BioPharmaceutical Company OIS @ ASCRS April 12, 2018 NASDAQ: EYPT Forward Looking SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationJefferies Healthcare Conference. June 2016
Jefferies Healthcare Conference June 2016 Forward Looking Statements This presentation contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation
More information2016 Summary Financial Results
ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2016 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE -------------------------------------------------------------------------------------------------- GENETIC-AF Phase
More informationAVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update
AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. November 4, 2016 AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter
More informationThe. Altascientist SEPTEMBER 2018 ISSUE NO. 4
The Altascientist SEPTEMBER 2018 ISSUE NO. 4 Altasciences has the perfect mix of innovator and generic drug development experience, with a thorough understanding of the regulatory complexities involved
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationFirst Quarter 2018 Financial Results & Update
First Quarter 2018 Financial Results & Update April 26, 2018 Forward-Looking Statements and Non-GAAP Financial Information 2 Certain statements set forth in this presentation constitute forward-looking
More informationBiopharmaceuticals Investor & Analyst Day
Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative
More informationCorporate Presentation March 2017
Corporate Presentation March 2017 Safe Harbor Statement This presentation (the Presentation ) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,
More informationTrends in Medication Management. Jayson Gallant, B.Pharm, M.Sc Pharmacist, Health Benefit Management
Trends in Medication Management Jayson Gallant, B.Pharm, M.Sc Pharmacist, Health Benefit Management Agenda Drug Claims Trends Legislative / Public Plan Initiatives Biosimilars Pipeline Focus on Oncology
More informationBIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationThe Potential For Litigation In New Era Of Biosimilars
The Potential For Litigation In New Era Of Biosimilars By Christian Frois, Richard Mortimer and Alan White; Analysis Group, Inc. Law360, New York (September 20, 2016, 4:06 PM EDT) Christian Frois Richard
More informationGlobal Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity
Global Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity Howard L. Levine, Ph.D. Eighth Annual BioProcess International Europe 2012 Apr 18-19 Prague, Czech Republic BioProcess Technology
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More information2018 ASCO Conference Call June 2, 2018
2018 ASCO Conference Call June 2, 2018 1 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the safe harbor provisions
More informationBiosimilar medicines rising to the cost challenge
Chapter 3 Biosimilar medicines rising to the cost challenge Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe. Biosimilar
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationBiotech Showcase 2016
1 Biotech Showcase 2016 Our Value Proposition Advancing broad product pipeline of biosimilars and next generation antibody therapeutics Proven track record in superior quality, efficient R&D and manufacturing
More informationAsia s Clout in Global Biosimilars
MIRAE ASSET LENS 4Q 2017 Mirae Asset Global Investments (Hong Kong) Asia Pacific Investment / Research Saniel Chandrawat, Senior Investment Analyst Sizing up the opportunity The global biosimilar market
More informationResults to be Presented at LDN WORLD Symposium in February Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13
Amicus Therapeutics Announces Positive Results from All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease Strong Proof-of-Concept Data for Chaperone
More informationInnovation and Sustainability: An integrated approach
Innovation and Sustainability: An integrated approach Karl Mahler Head of Investor Relations Dianne Young Sustainability Communications Swiss Sustainability Leaders SRI Conference Zurich, 4 October 2013
More informationGoldman Sachs Health Care Conference
Goldman Sachs Health Care Conference Laguna Niguel, California June 14, 2006 George Morrow Executive Vice President Global Commercial Operations Safe Harbor Statement This presentation contains forward-looking
More informationVince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016
Quality Management in a Virtual Environment Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Biosimilars - the second wave of biotech -an evolving regulatory
More informationNYSE American: PFNX. Corporate Presentation November 2018
NYSE American: PFNX Corporate Presentation November 2018 Pfenex Safe Harbor Statement This presentation, including the accompanying oral presentation (the Presentation ), includes forward-looking statements
More informationNHS BioValue: The Potential for a Landmark UK NHS Real World Evidence Study on Biosimilars
NHS BioValue: The Potential for a Landmark UK NHS Real World Evidence Study on Biosimilars Angela McFarlane Market Development Director, QuintilesIMS Angela.McFarlane@QuintilesIMS.com Copyright 2016 QuintilesIMS.
More informationJune 4, Jefferies Global Healthcare Conference
June 4, 2015 Jefferies Global Healthcare Conference Safe Harbor Statement The following presentation includes forward-looking statements within the meaning of the safe harbor provisions of the Private
More informationUniversity of Connecticut Student Managed Fund 2018 Analyst Report. Jonathan Stryjek & Michael Pehota
University of Connecticut Student Managed Fund 2018 Analyst Report Jonathan Stryjek & Michael Pehota Table of Contents 3 Report Highlights 4 Business Overview 5 Industry Overview and Competitive Positioning
More informationBiosimilars: A Year in Review
January 18, 2018 Webinar Series: s s: A Year in Review John Adkisson Principal Twin Cities Tasha Francis Associate Twin Cities Jenny Shmuel Associate Boston Overview s Series Introduction to the area of
More informationOvercoming Challenges in the Emerging Biosimilar Landscape
Overcoming Challenges in the Emerging Biosimilar Landscape Steven R. Feldman, M.D., Ph.D. Wake Forest University School of Medicine Winston Salem, North Carolina, USA Objectives Identify the safety and
More informationBiosimilars Update 4/23/2015. The Biosimilar Roadmap From concept to delivery. Conflict of Interest Disclosure. Collaborate Cultivate Educate
Collaborate Cultivate Educate Biosimilars Update Conflict of Interest Disclosure We have no actual or potential conflict of interest in relation to this program and presentation. Brad Patten Patrick Leary
More informationARCUSBIOSCIENCES,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,DC20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d) ofthesecuritiesexchangeactof1934 DateofReport(Dateofearliesteventreported):May9,2018 ARCUSBIOSCIENCES,INC.
More informationAre Biosimilars the Panacea for High Cost Specialty Drugs?
Are Biosimilars the Panacea for High Cost Specialty Drugs? Mid-sized Retirement and Healthcare Plan Management San Francisco, CA March 27, 2018 2018. Innovative Rx Strategies, LLC. All rights reserved.
More informationWebinar Series: Biosimilars. Biosimilars & IPR
March 24, 2016 Webinar Series: Biosimilars Biosimilars & IPR Attorney Photo Dorothy P. Whelan Principal Twin Cities Attorney Photo Brian D. Coggio Of Counsel New York Overview Biosimilars Series Introduction
More information5th Annual National Association of Specialty Pharmacy Annual Meeting and Educational Conference
5th Annual National Association of Specialty Pharmacy Annual Meeting and Educational Conference September 18-20, 2017 Washington, DC Biosimilars: Price, Policy & Outlook Ron Lanton III, Esq. President
More informationProfessor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011 1 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking
More informationJanuary 2019 Investor Presentation NASDAQ: ATRS
January 2019 Investor Presentation NASDAQ: ATRS Safe Harbor Statement This presentation contains forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation
More informationElena BM Breidenstein, PhD 21 April 2018
Discovery of a Novel Oral Antibiotic, DDS-01 (SMT-571), to Treat Multi-Drug Resistant Neisseria gonorrhoeae Enabled by a Proprietary Transposon Technology Elena BM Breidenstein, PhD 21 April 2018 Forward-Looking
More informationHatch-Waxman: Driving Access, Savings & Innovation
Hatch-Waxman: Driving Access, Savings & Innovation Introduction Thirty years ago, Congress sought to create a balance between access to lower cost generic medicines and incentives to innovate new and better
More informationPatent and regulatory issues in Biotech
2013-2017 Regimbeau Patent and regulatory issues in Biotech Frédérique FAIVRE PETIT Partner French and EP patent attorney Different levels of interplay Development Compound/first medical use Launch Marketing
More informationKey Activities. Ofer Reizes, Ph.D. Skills Development Director
Key Activities Ofer Reizes, Ph.D. Skills Development Director 1 Key Activities Core Question: What key activities required for your Value Propositions? Key Partners Key Activities Key Resources Value Proposition
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationMylan. Raymond James 40 th Annual Institutional Investors Conference March 05, 2019
Mylan Raymond James 40 th Annual Institutional Investors Conference March 05, 2019 Forward-Looking Statements This presentation contains forward-looking statements. These statements are made pursuant to
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Michael Severino Vice Chairman and President January 9, 2019 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation are, or
More informationComparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan
Comparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan The International Economic Forum of the Americas Serge Lapointe, Ph.D. Partner, Patent Agent June
More information